IONS Q2 2019 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+39.1% YoY

Gross Profit

$162M99.2% margin

Operating Income

-$19M-11.5% margin

Net Income

-$876,000-0.5% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-44.9%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$32M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.3B

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$118M	+39.1%
Gross Profit	$162M	$118M	+38.0%
Operating Income	-$19M	-$50M	+62.6%
Net Income	-$876,000	-$40M	+97.8%

Revenue Segments

Commercial

$88M35%

Research and Development Revenue Under Collaborative Agreements

$76M30%

SPINRAZA Royalties

$71M28%

TEGSEDI Product Sales

$10M4%

Licensing and Other Royalties

$8M3%